글로벌 에볼라 바이러스 감염 약물 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 에볼라 바이러스 감염 약물 시장

에볼라 바이러스 감염 약물 시장은 2021년에서 2028년까지의 예측 기간 동안 33.20%의 시장 성장을 목격할 것으로 예상됩니다. 에볼라 바이러스 감염 약물 시장에 대한 Data Bridge Market Research 보고서는 예측 기간 내내 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다. 에볼라 바이러스 감염 유병률의 증가는 에볼라 바이러스 감염 약물 시장의 성장을 가속화하고 있습니다.

에볼라 바이러스 감염은 인간과 비인간 영장류에서 4가지 다른 에볼라 바이러스 종에 의해 발생하는 심각한 치명적인 상태를 말합니다. 이 감염은 출혈열을 일으켜 내부 및 외부 출혈을 유발하여 여러 장기에 영향을 미칩니다. 초기 증상에는 인후통, 근육통 및 두통이 있습니다. 후기에는 구토, 발진 및 설사와 같은 증상이 나타납니다.

에볼라 바이러스 감염으로 고통받는 환자 수의 증가는 에볼라 바이러스 감염 약물 시장 성장을 견인하는 주요 요인 중 하나로 작용합니다. 에볼라 약물 및 백신 개발을 포함한 에볼라 연구에 대한 꾸준한 정부 지원과 진단 및 치료의 전반적인 과정을 개선하기 위한 연구 개발 활동에 대한 투자 증가는 에볼라 바이러스 감염 약물 시장 성장을 가속화합니다. 에볼라 바이러스 감염에 대한 신뢰할 수 있는 치료법이 부족하고 감염에 대한 인식이 커지면서 에볼라 바이러스 감염 약물 시장에 더욱 영향을 미칩니다. 또한 질병과 치료 옵션에 대한 대중의 인식, 의료 인프라 개선, 투자 증가 및 의료 지출 급증은 에볼라 바이러스 감염 약물 시장에 긍정적인 영향을 미칩니다. 나아가 치료 및 새로운 치료법에 대한 수요 증가는 2021년에서 2028년까지의 예측 기간 동안 에볼라 바이러스 감염 약물 시장 참여자에게 수익성 있는 기회를 확대합니다.

On the other hand, high cost associated with the treatment is expected to obstruct the Ebola virus infection drug market growth. The emergence of generic drugs of branded version and issues with patent expiration are projected to challenge the Ebola virus infection drug market in the forecast period of 2021-2028.

This Ebola virus infection drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Ebola virus infection drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Ebola Virus Infection Drug Market Scope and Market Size

The Ebola virus infection drug market is segmented on the basis of strain type, mechanism of action type, therapy type, novel drug type, vaccine type, route of administration and end- users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of strain type, the Ebola virus infection drug market is segmented into zaire, sudan, tai forest and bundibugyo virus.
• On the basis of mechanism of action type, the Ebola virus infection drug market is segmented into antiviral drug.
• On the basis of therapy type, the Ebola virus infection drug market is segmented into oxygen therapy.
• On the basis of novel drug type, the Ebola virus infection drug market is segmented into Zmapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537.
• On the basis of vaccine type, the Ebola virus infection drug market is segmented into Cad3-Zebov and Rvsv-Zebov.
• On the basis of route of administration, the Ebola virus infection drug market is segmented into oral, intravenous and others.
• On the basis of end- users, the Ebola virus infection drug market is segmented into hospitals, homecare, specialty clinics, online pharmacy, retail pharmacy and others.

Global Ebola Virus Infection Drug Market Country Level Analysis

The Ebola virus infection drug market is analyzed and market size information is provided by country, strain type, mechanism of action type, therapy type, novel drug type, vaccine type, route of administration and end- users as referenced above.

The countries covered in the global Ebola virus infection drug market report are the U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the Ebola virus infection drug market due to the advanced medical research scenario in the U.S.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The Ebola virus infection drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to Ebola virus infection drug market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the Ebola virus infection drug market in the growth period.

Competitive Landscape and Ebola Virus Infection Drug Market Share Analysis

The Ebola virus infection drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Ebola virus infection drug market.

에볼라 바이러스 감염 약물 시장 보고서에서 다루는 주요 기업은 Merck & Co., Inc., NewLink Genetics Corporation, Johnson & Johnson Private Limited, GlaxoSmithKline plc, Novavax, GeoVax, Mapp Biopharmaceutical, Arbutus Biopharma, Bavarian Nordic, Nanoviricides, INC, Sarepta Therapeutics, Chimerix, Biocryst Pharmaceuticals, INC, Hemispherx Biopharma, Inc., BioComo Incorporation, Peptineo, Bio-Excel, Geneone Life Sciences, IMV Inc., Etubics 등 국내 및 글로벌 기업입니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-41174